Diagnostic Potential of PET/MRI in Cardiac Sarcoidosis

St. Olavs Hospital

Status

Completed

Conditions

Sarcoidosis

Cardiomyopathies

Treatments

Diagnostic Test: 18F-GE180-PET/MRI

Diagnostic Test: 18F-FDG-PET/MRI

Study type

Interventional

Funder types

Other

Identifiers

NCT03561025

2017-000331-14 (EudraCT Number)

2016/883

Details and patient eligibility

About

The aim of the study is to find better and more specific non-invasive methods to diagnose and stage cardiac sarcoidosis with the use of advanced imaging modalities, simultaneous 3T MRI and PET. Cardiac sarcoidosis is a disease of possibly fatal outcome in young people. The use of a combined PET/MRI system with 18F-FDG and a new inflammation-tracer (18F-GE180) can become a future game changer.

Sarcoid induced focal inflammation in myocardium should show high 18F-GE180 uptake. 18F-GE180 PET scans will give reliable data about inflammatory sarcoidosis activity in the myocardium. 18F-GE180 PET is expected to improve diagnostic accuracy compared to 18F-FDG-PET and/or contrast enhanced MRI.

Enrollment

33 patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Heart department: Suspicion of myocardial sarcoidosis after contrast enhanced cardiac MRI
Lung department: Clinically verified lung and/or mediastinal sarcoidosis

Exclusion criteria

Known malignancies
Treatment for sarcoidosis started
Severe arrhythmia
Patients with pacemakers or defibrillator
Claustrophobia
Known alcohol or drug abuse
Kidney failure (eGFR < 30)
Weight > 120 kg
Diabetes Mellitus type I and II
Patients that take immunosuppressive or immunomodulatory medication for any reason